ArticleBladder cancer (Amsterdam, Netherlands)
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression.
Article in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity. The GALEAS Bladder (GB) gene panel covers several actionable mutations, including in FGFR3. Objective: To modify GB to detect FGFR3 fusions as well as single nucleotide variants and assess its potential as a urine-based companion diagnostic. We also study tissue-urine concordance and associations between FGFR3 genomic alterations and FGFR3 expression. Methods: Probes were added to GB covering the 3'-region of FGFR3. The new panel was used to analyse genomic DNA extracted from 158 frozen primary BCs. Mutation concordance was also analysed in 107 tumour-urine pairs. Associations between FGFR3 mutations and expression were analysed in 608 FFPE BCs with the Decipher Bladder transcriptome assay. Results and limitations: FGFR3-TACC3 fusions were found in 3/3 positive controls and 4/158 frozen BCs. Fusions were also detectable in genomic DNA from FFPE tumour and urine cell pellet DNA. All fusions were corroborated by PCR and Sanger sequencing. FGFR3 mutation status in urine was 94.4% concordant (95% CI 87.7-97.7%); GB detected mutations in urine with 92.1% sensitivity (95% CI 81.7-97.0%) at 97.7% specificity (95% CI 86.5-99.9). All FGFR3 mutations were associated with increased FGFR3 expression. This is a proof-of-principle study, rather than definitive evidence of utility as a companion diagnostic, with the need for fusion detection validation in larger patient cohorts. Conclusions: In addition to BC detection, a modified version of GB demonstrates feasibility for tissue and urine-based detection of FGFR3 fusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.